An expanded universe of cancer targets.

Abstract

The characterization of cancer genomes has provided insight into somatically altered genes across tumors, transformed our understanding of cancer biology, and enabled tailoring of therapeutic strategies. However, the function of most cancer alleles remains mysterious, and many cancer features transcend their genomes. Consequently, tumor genomic characterization does not influence therapy for most patients. Approaches to understand the function and circuitry of cancer genes provide complementary approaches to elucidate both oncogene and non-oncogene dependencies. Emerging work indicates that the diversity of therapeutic targets engendered by non-oncogene dependencies is much larger than the list of recurrently mutated genes. Here we describe a framework for this expanded list of cancer targets, providing novel opportunities for clinical translation.

• Authors: William C Hahn, Joel S Bader, Theodore P Braun, Andrea Califano, Paul A Clemons, Brian J Druker, Andrew J Ewald, Haian Fu, Subhashini Jagu, Christopher J Kemp, William Kim, Calvin J Kuo, Michael McManus, Gordon B Mills, Xiulei Mo, Nidhi Sahni, Stuart L Schreiber, Jessica A Talamas, Pablo Tamayo, Jeffrey W Tyner, Bridget K Wagner, William A Weiss, Daniela S Gerhard, Cancer Target Discovery and Development Network
• Journal: Cell (Cell) Vol. 184 Issue 5 Pg. 1142-1155 (03 04 2021) ISSN: 1097-4172 [Electronic] United States
• PMID: 33667368 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Review)
• Copyright: Copyright © 2021 Elsevier Inc. All rights reserved.

Topics

• Animals
• Clinical Trials as Topic
• Disease Models, Animal
• Drug Delivery Systems
• Genomics
• Humans
• Neoplasms (drug therapy, genetics, pathology)
• Tumor Escape (drug effects)
• Tumor Microenvironment (drug effects)